Mindfulness-Based interventions have increased in popularity in psychiatry, but the impact of these treatments on disorder-relevant biomarkers would greatly enhance efficacy and mechanistic evidence. If Generalized Anxiety Disorder (GAD) is successfully treated, relevant biomarkers should change, supporting the impact of treatment and suggesting improved resilience to stress. Seventy adults with GAD were randomized to receive either Mindfulness-Based Stress Reduction (MBSR) or an attention control class; before and after, they underwent the Trier Social Stress Test (TSST). Area-Under-the-Curve (AUC) concentrations were calculated for adrenocorticotropic hormone (ACTH) and pro-inflammatory cytokines. MBSR participants had a significantly greater reduction in ACTH AUC compared to control participants. Similarly, the MBSR group had a greater reduction in inflammatory cytokines' AUC concentrations. We found larger reductions in stress markers for patients with GAD in the MBSR class compared to control; this provides the first combined hormonal and immunological evidence that MBSR may enhance resilience to stress.

No abstract

Panic disorder with or without agoraphobia is a common, often chronic and refractory anxiety disorder. Although a number of pharmacotherapies are now indicated for panic disorder, many patients do not respond to available interventions. We hypothesized that duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI) that has greater initial noradrenergic effects than venlafaxine, would have broad efficacy for individuals with panic disorder. Fifteen individuals with panic disorder with or without agoraphobia received 8 weeks of open label duloxetine flexibly dosed from 60 to 120 mg per day. Duloxetine treatment resulted in significant anxiolysis as measured by the primary outcome measure, the Panic Disorder Severity Scale (PDSS) (paired t(df) = 4.02(14), P= 0.0013), as well as measures of generalized anxiety, depression and quality of life (all P < 0.05). Although definitive conclusions are limited due to its small open-label nature, this first prospective study provides preliminary support for the efficacy of duloxetine for panic disorder and suggests larger randomized controlled study is warranted.

ocial phobia is a significant fear of social interactions, whether individually or in groups. Situations that may induce fear include social conversations, meeting unfamiliar people, being observed while doing something such as eating or drinking in front of others, or engaging in formal performances such as giving a speech or playing an instrument. Approximately 11% of the population will suffer from social phobia at some time in their lives (Kessler, Petukhova, Sampson, Zaslavsky, & Wittchen, 2012). People with social phobia fear that they will do or say something that will be evaluated negatively by others. The extent and severity of fear in people with social phobia vary, but the symptoms significantly impair their social, occupational, and academic functioning. People with social phobia go to great lengths to hide their fears and try to hide the accompanying characteristic physiological symptoms such as a racing heart, sweating, and blushing. Blushing is particularly problematic because it is an anxious response that is clearly visible to others, resulting in an individual's feeling uncomfortable not just because of the social interaction but also because of worry that others will negatively evaluate this visible manifestation of anxiety. Thus, this creates a vicious cycle of distress-social anxiety, the belief that others will perceive one's distress, more anxiety-and this leads to a pattern of social avoidance and functional impairment.

No abstract